SCHEMBL3786255

SCHEMBL3786255

CCOC(=O)c1ccc2c(c1)[nH]c(=O)c1cccn12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 10/20 0.59
ALDH1A1 P00352 4/20 0.55
MAPT P10636 4/20 0.55
RAB9A P51151 2/20 0.55
PPARG P37231 1/20 0.55
NCOA2 Q15596 1/20 0.55
NCOA1 Q15788 1/20 0.55
AURKB Q96GD4 1/20 0.54
TP53 P04637 3/20 0.53
MAT2A P31153 1/20 0.47
KDM4E B2RXH2 3/20 0.47
HCRTR1 O43613 2/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
LMNA P02545 1/20 0.47
HPGD P15428 2/20 0.46
GLA P06280 1/20 0.46
GAA P10253 1/20 0.46
POLB P06746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29965297 1.00 PARP1 (0.59) PARP1ALDH1A1MAPTRAB9APPARG
SCHEMBL3339424 0.86 PARP1 (0.62) PARP1ALDH1A1AURKBTP53KDM4E
SCHEMBL29893230 0.86 PARP1 (0.62) PARP1ALDH1A1AURKBTP53KDM4E
SCHEMBL30902531 0.82 PARP1 (0.67) PARP1ALDH1A1MAPTAURKBTP53
SCHEMBL13056839 0.80 PARP1 (0.68) PARP1ALDH1A1MAPTAURKBTP53
SCHEMBL3784199 0.80 PARP1 (0.68) PARP1ALDH1A1AURKBTP53KDM4E
SCHEMBL3080392 0.79 PARP1 (0.62) PARP1AURKBTP53CDC7PLK4
SCHEMBL29965925 0.78 ALDH1A1 (0.55) PARP1ALDH1A1MAPTRAB9APPARG
SCHEMBL28895268 0.78 ALDH1A1 (0.55) PARP1ALDH1A1MAPTRAB9APPARG
SCHEMBL3338380 0.76 PARP1 (0.54) PARP1ALDH1A1AURKBTP53KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115368362-A Quinoxalinone derivatives as BTK inhibitors and application thereof 华东理工大学 2022-11-22 CN disclosed
US-20100298302-A1 NOVEL PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2010-11-25 US disclosed
WO-2010135571-A1 NOVEL PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2010-11-25 WO disclosed
US-20100298302-A1 NOVEL PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2010-11-25 US disclosed
WO-2010135571-A1 NOVEL PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2010-11-25 WO disclosed
US-20100298302-A1 NOVEL PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2010-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298302-A1 NOVEL PROTEIN KINASE MODULATORS PIM2, PIM1, PIM3 PARP1 1573/4885ALDH1A1 4648/4885MAPT 2534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.